Global Azacitidine Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 77.51 Billion |
 Market Size (Forecast Year) |
USD 142.41 Billion |
 CAGR |
% |
| Major Markets Players |
Global Azacitidine Market, By Type (99.5%,
Azacitidine Market Analysis and Size
Azacitidine is a class of medications known as demethylation. The rise in the number of people suffering from chronic diseases such as breast cancer and melanoma globally acts as one of the primary factors boosting the growth of azacitidine market. The increased recommendations by several medical professionals have grown too fast and do not work properly. The development of several new drugs by major market players further influences the market.
Data Bridge Market Research analyses that the azacitidine market is expected to reach USD 142.41 million by 2030, which is USD 77.51 million in 2022, and is expected to undergo a CAGR of 7.9% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Azacitidine Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (99.5%, <99.5%), Product (Vidaza, Generic Vidaza), Application (Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic Myelomonocytic leukemia (CMMoL), Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), AstraZeneca (U.K.), GSK plc (U.K.), H. Lundbeck A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), DAIICHI SANKYO COMPANY, LIMITED (Japan), Eisai Co., Ltd (Japan), Merz Pharma (Germany) |
|
Market Opportunities |
|
Market Definition
Azacitidine is the type of chemotherapy drug used to treat a group of blood or bone marrow disorders where the bone marrow fails to produce enough healthy blood cells. Several Individuals are suffering from MDS, and generally face complications such as anemia, infections, and easy bleeding or bruising. Azacitidine comes in the powder form to be mixed with water and injected subcutaneously or intravenously in a medical office or hospital outpatient department. It is generally injected once a day for 7 days.
Azacitidine Market Dynamics
Drivers
- Growing regulatory approval of drugs
Growing regulatory approval for the drugs that are used in the treatment of MDS treatment is projected to boost the market growth during the forecast period. For instance, Lupin received the U.S. FDA approval in November 2018 for its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is specified for treating patients with myelodysplastic syndromes (MDS). Furthermore, the U.S. FDA approved Inqovi tablets in July 2020 for treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This signifies an important advancement in treatment options for patients suffering from myelodysplastic syndrome (MDS) who previously used to receive intravenous therapy.
Opportunities
- Increasing Cancers of Cancer
Acute myeloid leukemia (AML) is often difficult to treat, particularly for older adults and those who don't respond well to standard chemotherapy treatment options. Multiple myeloma (MM) is also a type of cancer that is treated with azacitidine by slowing down the production of these abnormal white blood cells. This factor is boosting the market growth.
- Rising Awareness about the myelodysplastic syndrome (MDS) disease
Several government organizations and drug manufacturing companies are primarily focusing on spreading awareness about the myelodysplastic syndrome disease by providing funding for R&D of drugs which are used in the treatment of MDS and showing awareness programs about the disease. For instance, Grupo Biotoscana in October 2018, conducted a campaign to celebrate Myelodysplastic Syndrome World Awareness Day, on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease.
Restraints/Challenges
- Late Approvals from Organizations
There are numerous companies that cannot manufacture a drug unless the patent of a drug termintates. Thus, there are many chances that make the billion dollar drugs lose patents. This impedes the market growth.
This azacitidine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the azacitidine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Azacitidine Market Scope
The azacitidine market is segmented on the basis of type, product, application, route of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- 99.5%
- <99.5%
Product
- Vidaza
- Generic Vidaza
Application
- Refractory anemia (RA)
- Refractory anemia with excess blasts (RAEB)
- Chronic Myelomonocytic leukemia (CMMoL)
- Others
Route of Administration
- Injectable
- Oral
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End-User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Azacitidine Market Regional Analysis/Insights
The azacitidine market is analyzed and market size insights and trends are provided by type, product, application, route of administration, distribution channel and end user as referenced above.
The major countries covered in the azacitidine market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market because of the increasing healthcare expenditures and well-established healthcare infrastructure.
Asia-Pacific is considered to have the most lucrative period because of the increased consumption demand for active pharmaceutical ingredients.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Azacitidine Market Share Analysis
The azacitidine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to azacitidine market.
Key players operating in the azacitidine market include:
- Novartis AG (Switzerland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bausch Health Companies Inc. (Canada)
- AstraZeneca (U.K.)
- GSK plc (U.K.)
- H. Lundbeck A/S (Denmark)
- Takeda Pharmaceutical Company Limited (Japan)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Eisai Co., Ltd (Japan)
- Merz Pharma (Germany)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
